Sophie Schmitz, Managing Partner of Partners4Access is to chair a panel discussion on rare diseases at the BioIndustry Association or BIA’s event UK Bioscience Forum on October 18, 2018.
The event will take place at Queen Elizabeth II Conference Centre in Westminster, London.
Titled “Challenges and solutions for rare diseases”, the segment will discuss some of the challenges associated with rare disease drug discovery and the rationale behind companies choosing to focus their pipeline on rare and ultra-rare diseases. The panel includes Emily Crossley, Co-founder of Duchenne UK, Tim Guilliams, CEO of Healx, Catriona Crombie, Philanthropic Fund Manager from LifeArc and Sarepta Therapeutics’ UK and Ireland General Manager, Paul Cox.
The UK Bioscience Forum is attended by over 190 life science companies with 50 speakers sharing insights on challenges in research and development, intellectual property, market access, manufacturing expansions, communication in international markets and the impact of Brexit.
Sophie Schmitz, Managing Partner said, “UK Bioscience Forum is a great platform to further the debate on how to tackle the multiple challenges faced by the rare disease industry. The involvement of diverse stakeholder groups such as patient organisations, payers, new technology firms as well as the biotech industry ensures that the dialogue will incorporate different perspectives in its search for solutions.”
If you would like to register for the UK Bioscience Forum, please visit https://www.ukbioscienceforum.org/ .
P4A are specialists in orphan drug access, partnering with the biotechnology industry to support launches worldwide. Focus areas include: orphan drugs pricing and market access strategy; bespoke access roadmap; rare disease foresights; evidence mitigation solutions; access team excellence. As one of the only consultancies with comprehensive experience in cell and gene therapies, P4A are excellently placed to help clients successfully achieve access.
Through its initiatives, P4A are able to inform and shape the conversation around orphan drugs.
The team at P4A believe in a sustainable orphan drug, cell and gene therapy world. That means helping drive access to the most appropriate treatments for patients and physicians, a fair return on investment for manufacturers at an affordable proposition for payers.
For more information, please email P4A at email@example.com.
About the BIA
Established over 25 years ago at the infancy of biotechnology, the BioIndustry Association (BIA) is the trade association for innovative enterprises involved in UK bioscience. Members include emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector. The BIA represents the interests of its members to a broad section of stakeholders, from government and regulators to patient groups and the media. Our goal is to secure the UK’s position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people’s lives.
For further information, please go to www.bioindustry.org